Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN
Werte in diesem Artikel
LOS ANGELES, Feb. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws.
Shareholders who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.
CASE DETAILS: The Company allegedly made false and misleading statements to the market regarding taking part in insurance fraud in China. The Company faced significant legal exposure in China, eventually resulting in its China President being detained by law enforcement.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/final-deadline-for-the-astrazeneca-plc-securities-lawsuit---contact-the-djs-law-group-to-discuss-your-rights---azn-302381692.html
SOURCE DJS Law Group LLP
Ausgewählte Hebelprodukte auf AstraZeneca
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu AstraZeneca PLC
Analysen zu AstraZeneca PLC
Datum | Rating | Analyst | |
---|---|---|---|
20.02.2025 | AstraZeneca Outperform | Bernstein Research | |
19.02.2025 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
13.02.2025 | AstraZeneca Buy | UBS AG | |
12.02.2025 | AstraZeneca Hold | Deutsche Bank AG | |
11.02.2025 | AstraZeneca Outperform | Bernstein Research |
Datum | Rating | Analyst | |
---|---|---|---|
20.02.2025 | AstraZeneca Outperform | Bernstein Research | |
19.02.2025 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
13.02.2025 | AstraZeneca Buy | UBS AG | |
11.02.2025 | AstraZeneca Outperform | Bernstein Research | |
10.02.2025 | AstraZeneca Buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
12.02.2025 | AstraZeneca Hold | Deutsche Bank AG | |
07.02.2025 | AstraZeneca Halten | DZ BANK | |
07.02.2025 | AstraZeneca Hold | Deutsche Bank AG | |
06.02.2025 | AstraZeneca Neutral | UBS AG | |
06.02.2025 | AstraZeneca Hold | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
12.11.2024 | AstraZeneca Sell | UBS AG | |
07.11.2024 | AstraZeneca Sell | UBS AG | |
05.11.2024 | AstraZeneca Sell | UBS AG | |
05.11.2024 | AstraZeneca Sell | Deutsche Bank AG | |
05.11.2024 | AstraZeneca Sell | UBS AG |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AstraZeneca PLC nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen